Citigroup believes BioMarin's 6.5M share offering provides a buying opportunity ahead of the company's trial data releases. Citi notes BioMarin management stated that the financing is not intended to support any acquisitions in the near-term, and the firm keeps a Buy rating on the stock with a $49 price target.
Happy demi-anniversary, stock market rally. Will the honeymoon ever end?